• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DBVT alert in real time by email
    SC 13G/A 1 dbvt_sc13ga_2.htm SC 13G/A 1 ef20021615_sc13ga.htm SC 13G/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

    DBV TECHNOLOGIES S.A.
    (Name of Issuer)

    Ordinary shares, nominal value €0.10 per share
    (Title of Class of Securities)

    23306J200**
    (CUSIP Number)

    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **This is the CUSIP for the American Depositary Shares, each representing one-half of one Ordinary Share.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Continued on following pages
    Page 1 of 8 Pages



    CUSIP No. 23306J200
    Page 2 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
    BRAIDWELL LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)☐
    (b)☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    10,162,9611
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    10,162,9611
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10,162,9611
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%2
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IA, PN

    1 Consists of 3,300,000 Shares (as defined herein), Shares issuable upon the exercise of 6,010,000 immediately exercisable pre-funded warrants (“Warrants”) subject to the Beneficial Ownership Limitation (defined below), and 1,630,542 American Depositary Shares (“ADS”), all of which are directly owned by Braidwell Partners Master Fund LP. Each ADS represents the right to receive one-half of one Share. The Warrants are subject to a blocker which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 9.99% of the Shares outstanding as a result of the exercise (the “Beneficial Ownership Limitation”).
    2 Based on 96,498,927 Shares outstanding as of July 30, 2024, as reported in the Issuer’s quarterly report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission (the “SEC”) on July 30, 2024, plus the total number of Shares that the Reporting Persons have the right to acquire upon exercise of Warrants, subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.


    CUSIP No. 23306J200
    Page 3 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
    BRAIDWELL MANAGEMENT LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)☐
    (b)☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    10,162,9611
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    10,162,9611
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10,162,9611
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%2
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    HC, OO


    CUSIP No. 23306J200
    Page 4 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
    ALEXANDER T. KARNAL
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)☐
    (b)☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Connecticut
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    10,162,9611
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    10,162,9611
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10,162,9611
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%2
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN, HC


    CUSIP No. 23306J200
    Page 5 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
    BRIAN J. KREITER
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)☐
    (b)☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    10,162,9611
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    10,162,9611
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10,162,9611
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%2
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    HC, OO


    CUSIP No. 23306J200
    Page 6 of 8 Pages
    Item 1(a).
    Name of Issuer:

    DBV Technologies S.A.

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    107 Av. de la République
    92320 Châtillon France

    Item 2(a).
    Name of Person Filing

    This filing is being jointly filed by the Reporting Persons.

    Item 2(b).
    Address of Principal Business Office or, if None, Residence:

    The business address of each Reporting Person is:
    2200 Atlantic St
    4th Floor
    Stamford, CT 06902

    Item 2(c).
    Citizenship:

    Braidwell LP is a limited partnership organized under the laws of the State of Delaware. Braidwell Management LLC is a limited liability company organized under the laws of the State of Delaware. Alexander Karnal and Brian Kreiter are both citizens of the United States of America.

    Item 2(d).
    Title of Class of Securities:

    Ordinary shares, nominal value €0.10 per share (the “Shares”)

    Item 2(e).
    CUSIP Number:

    23306J200 (This is the CUSIP for the American Depositary Shares, each representing one-half of one Ordinary Share)

    Item 3.
    If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

    (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E)
    (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)


    CUSIP No. 23306J200
    Page 7 of 8 Pages
    Item 4.
    Ownership:

    Item 4(a)
    Amount Beneficially Owned:

    Items 5-9 of each cover page are incorporated by reference. As of September 30, 2024, each Reporting Person may be deemed to be the beneficial owner of 10,162,961 Shares, which amount consists of 3,300,000 Shares, Shares issuable upon the exercise of 60,010,000 Warrants subject to the Beneficial Ownership Limitation, and 1,630,542 ADS, all of which are directly owned by Braidwell Partners Master Fund LP.

    Item 4(b)
    Percent of Class:

    As of September 30, 2024, each Reporting Person may be deemed to beneficially own 9.99% of the Shares, which is calculated based on 96,498,927 Shares outstanding as of July 30, 2024, as reported in the Issuer’s quarterly report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on July 30, 2024, plus the total number of Shares that the Reporting Persons have the right to acquire upon exercise of Warrants, subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

    Item 4(c)
    Number of Shares as to which such person has:

    (i) Sole power to vote or direct the vote: 0
    (ii) Shared power to vote or direct the vote: 10,162,9611
    (iii) Sole power to dispose or direct the disposition of: 0
    (iv) Shared power to dispose or direct the disposition of: 10,162,9611

    Item 5.
    Ownership of Five Percent or Less of a Class:

    n/a

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person:

    n/a

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

    The information in Item 4 is incorporated herein.

    Item 8.
    Identification and Classification of Members of the Group:

    n/a

    Item 9.
    Notice of Dissolution of Group:

    n/a

    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    CUSIP No. 23306J200
    Page 8 of 8 Pages
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Nobvember 14, 2024


    BRAIDWELL MANAGEMENT LLC
    AS GENERAL PARTNER OF BRAIDWELL LP





    BY:
    /S/ MANISH K. MITAL


    NAME: MANISH K. MITAL


    TITLE: AUTHORIZED SIGNATORY




    BRAIDWELL MANAGEMENT LLC



    BY:
    /S/ MANISH K. MITAL


    NAME: MANISH K. MITAL


    TITLE: AUTHORIZED SIGNATORY






    ALEXANDER T. KARNAL

    /s/ ALEXANDER T. KARNAL






    BRIAN J. KREITER


    /s/ BRIAN J. KREITER



    Get the next $DBVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DBVT

    DatePrice TargetRatingAnalyst
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    12/3/2025$35.00Buy
    Guggenheim
    5/29/2025$7.25Sell
    Goldman
    1/4/2023Hold → Buy
    Societe Generale
    12/16/2022Neutral → Sell
    Goldman
    5/10/2022$6.00 → $1.50Buy → Neutral
    Goldman
    12/21/2021$8.00 → $5.00Market Outperform
    JMP Securities
    12/21/2021$14.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

    Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today announced that it has filed a new automatically effective shelf registration statement on Form S-3ASR (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"), which includes a base prospectus and a sales agreement prospectus supplement refreshing the Company’s previously established at-the-market offering program (the "ATM Program") by filing a prospectus supplement for sales of up to $150 million of American Depositary Shares ("ADS"). The ATM Prog

    7/17/26 5:00:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

    Châtillon, France, July 16, 2026 DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company (the "Company"), today announced the filing, for the semester ended June 30, 2026, of its Half-Year Report with the French market authority, "Autorité des Marchés Financiers" ("AMF"). The 2026 Half-Year Report can be consulted or downloaded from the Company’s website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only. About DBV Technologies DBV Technologies is a late-stage biopharmaceut

    7/16/26 4:10:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

    Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, July 16, at 5:00pm ET DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today reported financial results for the Second Quarter and Half-Year of 2026. The quarterly and Half-Year financial statements

    7/16/26 4:01:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lee Philina

    3 - DBV Technologies S.A. (0001613780) (Issuer)

    4/16/26 4:51:42 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Mohideen Pharis sold $2,595 worth of Ordinary Shares (534 units at $4.86), decreasing direct ownership by 0.37% to 144,995 units (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/2/26 4:30:20 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    1/14/26 4:33:18 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on DBV Technologies with a new price target

    Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

    5/29/25 8:17:33 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tasse Daniel bought $14,188 worth of Ordinary Shares (17,094 units at $0.83) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    3/11/24 4:15:38 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ndu Adora bought $1,624 worth of Ordinary Shares (1,825 units at $0.89) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/8/24 5:02:03 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    SEC Filings

    View All

    DBV Technologies S.A. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - DBV Technologies S.A. (0001613780) (Filer)

    7/16/26 5:02:04 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by DBV Technologies S.A.

    10-Q - DBV Technologies S.A. (0001613780) (Filer)

    7/16/26 4:08:51 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by DBV Technologies S.A.

    8-K - DBV Technologies S.A. (0001613780) (Filer)

    6/29/26 4:28:49 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Leadership Updates

    Live Leadership Updates

    View All

    DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

    Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026. "We are proud to be admitted into the CAC Mid 60 and SBF 120 Indices, which reflect the financial markets' recognition of our continued progress," stated Daniel Tassé, Chief Executive Officer of D

    3/24/26 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

    Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased

    10/30/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Financials

    Live finance-specific insights

    View All

    DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

    Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, July 16, at 5:00pm ET DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today reported financial results for the Second Quarter and Half-Year of 2026. The quarterly and Half-Year financial statements

    7/16/26 4:01:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026

    Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m. ET DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, July 16th, at 5:00 p.m. ET to review its second quarter 2026 financial results and provide a business update. Interested participants may access this call via the teleconferencing numbers below and by asking to join the DBV Technologies Second Quarter 2026 Results call: United States: +1-877-344-8082 International: +1-2

    7/14/26 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

    Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing DBV has been engaged in extensive discussions with the FDA in preparation of its BLA for the VIASKIN® Peanut Patch in children aged four through seven yearsThe objective of the detailed, iterative engagement was to ensure a complete, efficient, and timely FDA review of the BLA, once submittedThe Agency has not requested additional dataDBV will take additional time to incorporate the FDA feedback and anticipates submitting the BLA in the third quarter of 2026D

    6/29/26 4:00:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    2/14/24 8:56:45 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    2/14/24 4:06:12 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care